A 2018 review of 16 studies of cannabis-centered medicines for neuropathic suffering, almost all of which tested a cannabinoid preparing termed nabiximols (manufacturer title Sativex; a mouth spray containing both of those THC and CBD which is approved in a few nations but not in America), discovered very low- to moderate-excellent proof that these